Review by a German commission also found major benefits in patients who had not responded to prior treatment with other medications.
Although it is widely understood that hepatitis B virus (HBV) and hepatitis C virus (HCV) are the leading causes of liver cirrhosis and liver cancer, an alarming number of HBV and HCV carriers have unhealthy habits that result in poor liver health.
The costs of Medicare associated with Sovaldi (sofosbuvir), an emerging hepatitis C drug, will vary depending on how many people are given the treatment, a blog in Health Affairs found.
The European Commission (EU) has granted Bristol-Myers Squibb’s Daklinza (daclatasvir) approval for an all-oral drug regimen for the treatment of four genotypes of chronic hepatitis C infection.
Surgeons transplanted a kidney from a donor who had hepatitis C to a recipient who also has the disease in what is believed to be the first of its kind in the state of Utah.
With the recent approval of new hepatitis C treatments, payers are increasingly concerned with controlling costs in this category through policies that may affect treatment decisions.